BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Inogen Secures $20 Million in Financing Led by Novo Nordisk A/S (NVO)


4/13/2012 7:26:04 AM

SANTA BARBARA, Calif., April 12, 2012 -- /PRNewswire/ -- Inogen, Inc., a manufacturer and accredited homecare provider of oxygen therapy equipment and services, announced that it has secured $20 million in equity financing from a group of investors led by Novo A/S. The funds will support Inogen's continued growth and build upon its position within the homecare community as a leading manufacturer and provider of innovative oxygen technology.

Since its accreditation as a national homecare provider for oxygen therapy in 2009, Inogen has setup thousands of individuals with its innovative oxygen technology. Inogen is proud to have changed the lives of oxygen therapy users by replacing their cumbersome legacy equipment with newer technology such as portable oxygen concentrators, thereby restoring their freedom and independence.

Raymond Huggenberger, Inogen CEO, said, "Inogen is well positioned for sustained growth over the coming years and this latest round of financing will ensure our operations continue to exceed customer expectations as the demand perpetuates for Inogen's products and services."

Inogen plans to use the new capital primarily to expand its sales and patient support resources, spread awareness among oxygen therapy users and also further solidify its market position by investing in R&D and the commercialization of innovative new products to improve the quality of life of oxygen users around the world.

Denmark-based Novo A/S, wholly owned by the Novo Nordisk Foundation, is an existing investor in Inogen. Heath Lukatch, Novo Partner and Inogen Chairman of the Board, said, "Inogen has created a unique success model rooted in patient satisfaction that is rarely found in the therapeutic oxygen industry and Novo is proud to support Inogen's vision and its substantial growth to meet market demand."

Inogen is innovation in oxygen therapy. Our mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes.

Corporate website: www.inogen.net Product and Service website: www.inogenone.com

SOURCE Inogen, Inc.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->